Pattern Bioscience Inc., Austin, TX, USA
DX FOR RAPID ID/AST
SINGLE CELL BIOMETRIC ANALYSIS
Pattern Bioscience (formerly Klaris Diagnostics) is developing a rapid identification and antimicrobial susceptibility test (ID/AST) to diagnose drug resistant infections quickly. Pattern’s technology combines single cell analysis with deep learning to deliver a fast and definitive diagnosis to guide antibiotic treatment decisions. The approach involves the encapsulation of individual microbial cells into pico-scale droplets with a cell viability dye that concentrates within the droplet environment and produces an easily detectable fluorescent signal in the presence of a live cell. Digital CultureTM technology enables phenotypic susceptibility testing across all common bacterial infections, thereby maximizing potential to improve antibiotic prescribing.
Current Development Stage: Development
CARB-X Investment: Initial investment of up to $6.8m with potential option payments up to $15.1m.
Initial CARB-X Investment Date: August 1, 2019
Read the Spotlight on Science about Pattern